{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:13Z","timestamp":1794047413566,"version":"4.8.0"},"reference-count":51,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is a malignancy of thymic T-cell precursors. Overexpression of oncogenic transcription factor TAL1 is observed in 40-60% of human T-ALL cases, frequently together with activation of the NOTCH1 and PI3K-AKT pathways. In this study, we performed chemical screening to identify small molecules that can inhibit the enhancer activity driven by TAL1 using the GIMAP enhancer reporter system. Among approximately 3,000 compounds, PIK- 75, a known inhibitor of PI3K and CDK, was found to strongly inhibit the enhancer activity. Mechanistic analysis demonstrated that PIK-75 blocks transcriptional activity, which primarily affects TAL1 target genes as well as AKT activity. TAL1-positive, AKT-activated T-ALL cells were very sensitive to PIK-75, as evidenced by growth inhibition and apoptosis induction, while T-ALL cells that exhibited activation of the JAK-STAT pathway were insensitive to this drug. Together, our study demonstrates a strategy targeting two types of core machineries mediated by oncogenic transcription factors and signaling pathways in T-ALL.<\/jats:p>","DOI":"10.3324\/haematol.2022.280761","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T03:37:48Z","timestamp":1662608268000},"page":"367-381","source":"Crossref","is-referenced-by-count":11,"title":["Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"108","author":[{"given":"Fang Qi","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Si-Yu","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yokomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Zi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelaine Skolastika","family":"Theardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen Eng Juh","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Hao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Sanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"44016","doi-asserted-by":"crossref","unstructured":"Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997; 278(5340):1059-1064.","DOI":"10.1126\/science.278.5340.1059"},{"key":"44017","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005; 23(26):6306-6315.","DOI":"10.1200\/JCO.2005.05.047"},{"key":"44018","doi-asserted-by":"crossref","unstructured":"Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008; 8(5):380-390.","DOI":"10.1038\/nri2304"},{"key":"44019","doi-asserted-by":"crossref","unstructured":"Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2008; 143(2):153-168.","DOI":"10.1111\/j.1365-2141.2008.07314.x"},{"key":"44020","doi-asserted-by":"crossref","unstructured":"Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016; 16(8):494-507.","DOI":"10.1038\/nrc.2016.63"},{"key":"44021","doi-asserted-by":"crossref","unstructured":"Brown L, Cheng JT, Chen Q. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J. 1990; 9(10):3343-3351.","DOI":"10.1002\/j.1460-2075.1990.tb07535.x"},{"key":"44022","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Staunton J. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002; 1(1):75-87.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"44023","doi-asserted-by":"crossref","unstructured":"Gianni F, Belver L, Ferrando A. The genetics and mechanisms of T-cell acute lymphoblastic leukemia. Cold Spring Harb Perspect Med. 2020; 10(3):a035246.","DOI":"10.1101\/cshperspect.a035246"},{"key":"44024","doi-asserted-by":"crossref","unstructured":"Sanda T, Lawton LN, Barrasa MI. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012; 22(2):209-221.","DOI":"10.1016\/j.ccr.2012.06.007"},{"key":"44025","doi-asserted-by":"crossref","unstructured":"Tan TK, Zhang C, Sanda T. Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia. Int J Hematol. 2019; 109(1):5-17.","DOI":"10.1007\/s12185-018-2518-z"},{"key":"44026","doi-asserted-by":"crossref","unstructured":"Tan SH, Yam AW, Lawton LN. TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. Leukemia. 2016; 30(4):959-962.","DOI":"10.1038\/leu.2015.195"},{"key":"44027","doi-asserted-by":"crossref","unstructured":"Leong WZ, Tan SH Ngoc PCT. ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis. Genes Dev. 2017; 31(23-24):2343-2360.","DOI":"10.1101\/gad.302646.117"},{"key":"44028","doi-asserted-by":"crossref","unstructured":"Liau WS, Tan SH Ngoc PCT. Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Leukemia. 2017; 31(8):1798-1807.","DOI":"10.1038\/leu.2016.392"},{"key":"44029","doi-asserted-by":"crossref","unstructured":"Weng AP, Ferrando AA, Lee W. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-271.","DOI":"10.1126\/science.1102160"},{"key":"44030","doi-asserted-by":"crossref","unstructured":"Liu Y, Easton J, Shao Y. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017; 49(8):1211-1218.","DOI":"10.1038\/ng.3909"},{"key":"44031","doi-asserted-by":"crossref","unstructured":"Gutierrez A, Sanda T, Grebliunaite R. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009; 114(3):647-650.","DOI":"10.1182\/blood-2009-02-206722"},{"key":"44032","doi-asserted-by":"crossref","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017; 14(4):417-419.","DOI":"10.1038\/nmeth.4197"},{"key":"44033","doi-asserted-by":"crossref","unstructured":"Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 2015; 4:1521.","DOI":"10.12688\/f1000research.7563.1"},{"key":"44034","doi-asserted-by":"crossref","unstructured":"Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol. 2014; 32(9):896-902.","DOI":"10.1038\/nbt.2931"},{"key":"44035","doi-asserted-by":"crossref","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550.","DOI":"10.1186\/s13059-014-0550-8"},{"key":"44036","doi-asserted-by":"crossref","unstructured":"Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics. 2019; 35(12):2084-2092.","DOI":"10.1093\/bioinformatics\/bty895"},{"key":"44037","doi-asserted-by":"crossref","unstructured":"Subramanian A, Tamayo P, Mootha VK. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.","DOI":"10.1073\/pnas.0506580102"},{"key":"44038","doi-asserted-by":"crossref","unstructured":"Chen EY, Tan CM, Kou Y. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013; 14:128.","DOI":"10.1186\/1471-2105-14-128"},{"key":"44039","doi-asserted-by":"crossref","unstructured":"Kwiatkowski N, Zhang T, Rahl PB. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014; 511(7511):616-620.","DOI":"10.1038\/nature13393"},{"key":"44040","doi-asserted-by":"crossref","unstructured":"Knight ZA, Gonzalez B, Feldman ME. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006; 125(4):733-747.","DOI":"10.1016\/j.cell.2006.03.035"},{"key":"44041","doi-asserted-by":"crossref","unstructured":"Thomas D, Powell JA, Vergez F. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood. 2013; 122(5):738-748.","DOI":"10.1182\/blood-2012-08-447441"},{"key":"44042","doi-asserted-by":"crossref","unstructured":"O'Neil J, Grim J, Strack P. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007; 204(8):1813-1824.","DOI":"10.1084\/jem.20070876"},{"key":"44043","doi-asserted-by":"crossref","unstructured":"De Keersmaecker K, Porcu M, Cox L. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica. 2014; 99(1):85-93.","DOI":"10.3324\/haematol.2013.088674"},{"key":"44044","doi-asserted-by":"crossref","unstructured":"Dempster JM, Boyle I, Vazquez F. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021; 22(1):343.","DOI":"10.1186\/s13059-021-02540-7"},{"key":"44045","doi-asserted-by":"crossref","unstructured":"Meyers RM, Bryan JG, McFarland JM. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017; 49(12):1779-1784.","DOI":"10.1038\/ng.3984"},{"key":"44046","doi-asserted-by":"crossref","unstructured":"Dempster J, Rossen J, Kazachkova M. Extracting biological insights from the Project Achilles Genome-Scale CRISPR screens in cancer cell lines. bioRxiv. 2019. Publisher Full Text|","DOI":"10.1101\/720243"},{"key":"44047","doi-asserted-by":"crossref","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508.","DOI":"10.1038\/s41586-019-1186-3"},{"key":"44048","doi-asserted-by":"crossref","unstructured":"An J, Huang YC, Xu QZ. DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression. BMC Mol Biol. 2010; 11:18.","DOI":"10.1186\/1471-2199-11-18"},{"key":"44049","doi-asserted-by":"crossref","unstructured":"Kusy S, Gerby B, Goardon N. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia. J Exp Med. 2010; 207(10):2141-2156.","DOI":"10.1084\/jem.20100745"},{"key":"44050","doi-asserted-by":"crossref","unstructured":"Chipumuro E, Marco E, Christensen CL. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014; 159(5):1126-1139.","DOI":"10.1016\/j.cell.2014.10.024"},{"key":"44051","doi-asserted-by":"crossref","unstructured":"Loven J, Hoke HA, Lin CY. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153(2):320-334.","DOI":"10.1016\/j.cell.2013.03.036"},{"key":"44052","doi-asserted-by":"crossref","unstructured":"Ghazawi FM, Faller EM, Parmar P, El-Salfiti A, MacPherson PA. Suppressor of cytokine signaling (SOCS) proteins are induced by IL-7 and target surface CD127 protein for degradation in human CD8 T cells. Cell Immunol. 2016; 06-307:41-52.","DOI":"10.1016\/j.cellimm.2016.07.002"},{"key":"44053","doi-asserted-by":"crossref","unstructured":"Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine\/threonine kinases in cancer. Med Res Rev. 2014; 34(1):136-159.","DOI":"10.1002\/med.21284"},{"key":"44054","doi-asserted-by":"crossref","unstructured":"Kimura S, Seki M, Kawai T. DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes. Leukemia. 2020; 34(4):1163-1168.","DOI":"10.1038\/s41375-019-0626-2"},{"key":"44055","doi-asserted-by":"crossref","unstructured":"Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood. 2017; 129(9):1113-1123.","DOI":"10.1182\/blood-2016-10-706465"},{"key":"44056","doi-asserted-by":"crossref","unstructured":"Bornschein S, Demeyer S, Stirparo R. Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system. Leukemia. 2018; 32(4):941-951.","DOI":"10.1038\/leu.2017.328"},{"key":"44057","doi-asserted-by":"crossref","unstructured":"Vicente C, Schwab C, Broux M. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica. 2015; 100(10):1301-1310.","DOI":"10.3324\/haematol.2015.130179"},{"key":"44058","doi-asserted-by":"crossref","unstructured":"Vanden Bempt M, Demeyer S, Broux M. Cooperative enhancer activation by TLX1 and STAT5 drives development of NUP214-ABL1\/TLX1-positive T cell acute lymphoblastic leukemia. Cancer Cell. 2018; 34(2):271-285.e7.","DOI":"10.1016\/j.ccell.2018.07.007"},{"key":"44059","doi-asserted-by":"crossref","unstructured":"Palomero T, Sulis ML, Cortina M. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007; 13(10):1203-1210.","DOI":"10.1038\/nm1636"},{"key":"44060","doi-asserted-by":"crossref","unstructured":"Sanda T, Li X, Gutierrez A. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood. 2010; 115(9):1735-1745.","DOI":"10.1182\/blood-2009-07-235143"},{"key":"44061","doi-asserted-by":"crossref","unstructured":"Simioni C, Neri LM, Tabellini G. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012; 26(11):2336-2342.","DOI":"10.1038\/leu.2012.136"},{"key":"44062","doi-asserted-by":"crossref","unstructured":"King B, Trimarchi T, Reavie L. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013; 153(7):1552-1566.","DOI":"10.1016\/j.cell.2013.05.041"},{"key":"44063","doi-asserted-by":"crossref","unstructured":"Roderick JE, Tesell J, Shultz LD. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014; 123(7):1040-1050.","DOI":"10.1182\/blood-2013-08-522698"},{"key":"44064","doi-asserted-by":"crossref","unstructured":"Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia. 2009; 23(8):1374-1377.","DOI":"10.1038\/leu.2009.75"},{"key":"44065","doi-asserted-by":"crossref","unstructured":"Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nat Rev Cancer. 2022; 22(1):5-24.","DOI":"10.1038\/s41568-021-00411-8"},{"key":"44066","doi-asserted-by":"crossref","unstructured":"Talekar M, Ganta S, Amiji M. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy. Int J Pharm. 2013; 450(1-2):278-289.","DOI":"10.1016\/j.ijpharm.2013.04.057"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280761\/74842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280761\/75236","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10792\/74842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:20Z","timestamp":1794045740000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.280761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.280761","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,8]]}}}